Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;29(3):244-250.
doi: 10.5005/jp-journals-10071-24899. Epub 2025 Feb 28.

Utility of Serum Prolactin Levels as a Marker for Disease Severity and Short-term Prognosis in Patients with Cirrhosis: A Prospective Observational Study

Rajneesh Singh  1 , Ramu Ramadoss  1 , Pazhanivel Mohan  2 , Balasubramaniyan Vairappan  3
Affiliations

Utility of Serum Prolactin Levels as a Marker for Disease Severity and Short-term Prognosis in Patients with Cirrhosis: A Prospective Observational Study

Rajneesh Singh et al. Indian J Crit Care Med. 2025 Mar.

Abstract

Background: Cirrhosis, a leading cause of global mortality, necessitates an accurate assessment of disease severity and prognosis. While traditional scoring systems like Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) are used to assess the severity, specific biomarkers are lacking. This study explores serum prolactin levels as a potential biomarker for evaluating cirrhosis severity and predicting short-term mortality.

Methods: A prospective observational study was conducted from December 2021 to December 2023. After a thorough clinical examination, serum prolactin levels were measured. The correlation between prolactin levels and established severity scores [CTP, MELD, chronic liver failure consortium organ failure (CLIF-C OF), and MELD-sodium (MELD-Na)] was analyzed. The study also evaluated the prognostic value of prolactin levels in predicting 28-day and 90-day mortality.

Results: A total of 90 patients with liver cirrhosis were included. There were 82% men, with a mean age of 47.6 years. Alcohol was the most common cause of cirrhosis (73%). The median (interquartile range (IQR)) serum prolactin level was 29 (10-54) ng/mL, with higher levels correlating with increased disease severity: CTP (r = 0.73), MELD (r = 0.64), MELD-Na (r = 0.67), and CLIF-C OF (r = 0.82) scores. Elevated prolactin levels were significantly associated with increased mortality, with an area under the receiver operating characteristic curve of 0.83 for predicting 28-day mortality and 0.79 for 90-day mortality. A prolactin cut-off of 35.12 ng/mL demonstrated high sensitivity (93% and 77%, respectively) and specificity (63% and 72%, respectively) for 28-day and 90-day mortality prediction.

Conclusion: Serum prolactin levels significantly correlated with the severity of cirrhosis and also effectively predicted the short-term mortality. Prolactin may offer a noninvasive and cost-effective adjunct for severity assessment and short-term prognosis in cirrhosis.

How to cite this article: Singh R, Ramadoss R, Mohan P, Vairappan B. Utility of Serum Prolactin Levels as a Marker for Disease Severity and Short-term Prognosis in Patients with Cirrhosis: A Prospective Observational Study. Indian J Crit Care Med 2025;29(3):244-250.

Keywords: Child-Turcotte-Pugh score; Chronic liver failure consortium organ failure score; Cirrhosis; Model for end-stage liver disease; Model for end-stage liver disease-sodium; Prolactin; Short-term mortality.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: NoneConflict of interest: None

Figures

Fig. 1
Fig. 1
Study flow diagram
Fig. 2
Fig. 2
Scatter plot between serum prolactin and CTP score
Fig. 3
Fig. 3
Box–Whisker plot between serum prolactin and HE grades
Figs 4A and B
Figs 4A and B
The AUROCs of serum prolactin and different severity scores to predict: (A) 28-day mortality and (B) 90-day mortality
See this image and copyright information in PMC

References

    1. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–537. doi: 10.1016/j.jhep.2023.03.017. - DOI - PubMed
    1. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228. doi: 10.1016/S2468-1253(19)30342-5. - DOI - PMC - PubMed
    1. Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12–19. doi: 10.1177/0269216307087148. - DOI - PubMed
    1. Velissaris D, Karanikolas M, Kalogeropoulos A, Solomou E, Polychronopoulos P, Thomopoulos K, et al. Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic encephalopathy. World J Gastroenterol. 2008;14(26):4190–4195. doi: 10.3748/wjg.14.4190. - DOI - PMC - PubMed
    1. Gonzales PH, Rhoden CR, Luz C, Corrêa G, Barbosa-Coutinho LM, Oliveira MC. Male gonadal function, prolactin secretion and lactotroph population in an experimental model of cirrhosis. Braz J Med Biol Res. 2007;40(10):1383–1388. doi: 10.1590/s0100-879x2006005000150. - DOI - PubMed

LinkOut - more resources